Evidence map›Paper›PMID 40428339›Full record

ArticleGenes2025

Characterization of Extrachromosomal Circular DNA in Primary and Cisplatin-Resistant High-Grade Serous Ovarian Cancer.

Youya Wang, He Li, Qinglan Li, Yi Li, Hao Wu, Yan Ge, Xingnuo Zhu, Zhiguo Zheng, Zhongsheng Sun

Abstract read
In one paragraph

Article in Genes, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Youya WangInstitute of Genomic Medicine, Wenzhou Medical University, Wenzhou 325000, China.
He LiInstitute of Genomic Medicine, Wenzhou Medical University, Wenzhou 325000, China.
Qinglan LiInstitute of Zoology, Chinese Academy of Sciences, Beijing 100101, China.
Yi LiInstitute of Zoology, Chinese Academy of Sciences, Beijing 100101, China.
Hao WuInstitute of Genomic Medicine, Wenzhou Medical University, Wenzhou 325000, China.
Yan GeInstitute of Genomic Medicine, Wenzhou Medical University, Wenzhou 325000, China.
Xingnuo ZhuInstitute of Genomic Medicine, Wenzhou Medical University, Wenzhou 325000, China.
Zhiguo ZhengHangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou 310022, China.ORCID 0000-0003-2142-8367
Zhongsheng SunInstitute of Genomic Medicine, Wenzhou Medical University, Wenzhou 325000, China.

Funding

National Natural Science Foundation of China 32170650
6 · The paper itself

Abstract

backgroundCisplatin resistance is a major cause of tumor recurrence and mortality in high-grade serous ovarian cancer (HGSOC). Extrachromosomal circular DNA (eccDNA) has emerged as a critical factor in tumor evolution and drug resistance. However, the specific contribution of eccDNA to cisplatin resistance in HGSOC remains unclear.

methodsWe performed whole-genome sequencing, Circle-Seq, and RNA-Seq in four pairs of primary and cisplatin-resistant (cisR) HGSOC cell lines to characterize genome-wide eccDNA distribution and features. Functional enrichment analyses were subsequently conducted on differentially expressed eccDNA-related genes.

resultsIn the SKOV3 cisR cell line, we identified a large extrachromosomal circular DNA (ecDNA) carrying the

conclusionsOur findings suggest that eccDNAs, particularly ecDNA amplifications like

Indexed as

CisplatinCystadenocarcinoma, SerousDNA, CircularDrug Resistance, NeoplasmOvarian NeoplasmsAntineoplastic AgentsCell Line, TumorFemaleGene Expression Regulation, NeoplasticHumansHypoxia-Inducible Factor 1, alpha SubunitAntineoplastic AgentsCisplatinDNA, CircularHIF1A protein, humanHypoxia-Inducible Factor 1, alpha Subunitcircle-Seqcisplatin resistanceeccDNAHGSOC

Identifiers

PMID40428339
PMCPMC12111702

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.